Grandisin induces apoptosis in leukemic K562 cells

AUTOR(ES)

Cortez, Alane Pereira, Menezes, Elizabeth Gomes Paulino, Benfica, Polyana Lopes, Santos, Alexandre Pereira dos, Cleres, Larissa Moreira, Ribeiro, Higor de Oliveira, Lima, Eliana Martins, Kato, Massuo Jorge, Valadares, Marize Campos

FONTE

Braz. J. Pharm. Sci.

DATA DE PUBLICAÇÃO

20/04/2017

RESUMO

Abstract In this study, the potential antileukemic activity of grandisin, a lignan extracted from Piper solmsianum, was evaluated against the leukemic line K562. The cytotoxicity of grandisin (0.018 to 2.365 µM) was evaluated in K562 and normal peripheral blood lymphocytes by Trypan Blue Exclusion and MTT methods after 48h exposure to the drug. In both methods, cellular viability was concentration-dependent and the IC50 values were lower than 0.85µM. Analysis of K562 cells after treatment with grandisin showed that the cell cycle was arrested in the G1 phase with a 12.31% increase, while both S and G2 phases decreased. Morphological studies conducted after the exposure of K562 to grandisin revealed changes consistent with the apoptosis process, which was confirmed by anexin V stain and caspase activation. Thus, lignan grandisin showed antileukemic activities against the K562 cell line and the cell death process occurred via apoptosis.

Documentos Relacionados

• Calcitonin receptor gene expression in K562 chronic myelogenous leukemic cells
• Erythroid Differentiation Sensitizes K562 Leukemia Cells to TRAIL-Induced Apoptosis by Downregulation of c-FLIP
• Persistent infection of K562 cells by encephalomyocarditis virus.
• Differential expression of human globin genes introduced in K562 cells.
• K562 cells implicate increased chromatin accessibility in Alu transcriptional activation